| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.2K | 2.1% | 3.5% |
| Total Income | 1.3K | 4.3% | 12.3% |
| Expenditure | 1.1K | 3.0% | 0.8% |
| PBT | 245.51 | 59.3% | 117.5% |
| Net Profit | 208.12 | 58.2% | 131.1% |
| OPM | 19.47% | 1.22pp | 18.89pp |
| NPM | 15.99% | 5.45pp | 8.31pp |
| EPS | 21.93 | 58.5% | 129.4% |
Strides Pharma Science Ltd Reports Highest Ever Quarterly EBITDA of Rs.2,359 million in Q3 FY26
30 Jan 2026 · 30 Jan, 12:56 pm
Summary
Strides Pharma Science Ltd announced its consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a revenue of 11,946 million, a gross margin of 7,317 million, and an EBITDA of 2,359 million. The operational PAT and operational EPS registered a growth of ~38% YoY.
Key Highlights
- 1
Revenue at 11,946 million, grew 3.6% YoY
- 2
Absolute gross margin at 7,317 million, grew 8.6% YoY
- 3
Gross margin improved to 61.2%, up 280bps YoY
- 4
EBITDA grew 12.2% YoY to 2,359 million, EBITDA margin at 19.8%, grew 160bps YoY
- 5
Ex-US Market Revenue at $64m, reported a strong growth of 20% YoY
- 6
Operational PAT at 1,282 million, Grew 38.6% YoY
- 7
Operational EPS at 13.9
Management Comments
Badree Komandur
MD & Group CEO
Strides continues to deliver a strong performance in Q3FY26 with growth primarily driven by the Other Regulated Markets and Growth Markets. Our strong focus on profitability resulted in gross margin expansion of 280bps YoY, and EBITDA margin increase of 160bps YoY to 19.8%. Operational PAT and Operational EPS registered a growth of ~38% YoY. This performance demonstrates our consistent execution as we continue to invest in sustainable, long-term growth.
Informational and educational content only. Not investment advice.